{"id":48229,"date":"2012-06-25T12:11:22","date_gmt":"2012-06-25T12:11:22","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/pathway-genomics-partners-with-dasa-the-largest-private-medical-diagnostics-company-in-brazil.php"},"modified":"2012-06-25T12:11:22","modified_gmt":"2012-06-25T12:11:22","slug":"pathway-genomics-partners-with-dasa-the-largest-private-medical-diagnostics-company-in-brazil","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/genetic-medicine\/pathway-genomics-partners-with-dasa-the-largest-private-medical-diagnostics-company-in-brazil.php","title":{"rendered":"Pathway Genomics Partners with DASA, the Largest Private Medical Diagnostics Company in Brazil"},"content":{"rendered":"<p><p>    SAN DIEGO--(BUSINESS WIRE)--  <\/p>\n<p>        Pathway Genomics Corporation, a San Diego-based genetic    testing laboratory, has partnered with     Diagnsticos da Amrica (DASA), the largest private medical    diagnostics company in Latin America and the fourth largest    provider of diagnostic services in the world. Based in Brazil,    DASAs clinical analysis division collects samples from more    than 500 patient service centers and has 11 central    laboratories. DASAs brands include Alta Excelncia    Diagnstica, Delboni Auriemo, Lavoisier, CDPI, Srgio Franco,    Pasteur, Exame and others. Through this partnership, physicians    have access to Pathways valuable genetic testing services,    bringing additional personalized care to more than 180 million    people in Brazil.  <\/p>\n<p>    Pathways vision is to responsibly reveal personalized and    actionable genetic information in order to globally educate,    inform and improve health and well-being, said Dr. Michael    Nova, Pathways chief medical officer. Our alignment with DASA    is a major part of this vision, and we are excited to help    bring this scientifically-advanced technology to the people of    Brazil.  <\/p>\n<p>    Specifically, through DASA, physicians in Brazil now have    access to multiple genetic tests, including:  <\/p>\n<p>    The partnership between DASA and Pathway represents a    milestone in Brazilian medicine, ensuring access to predictive    genetic tests through an advanced and innovative technology,    said Dr. Octvio Fernandes, DASAs chief operating officer.    DASA is a reference in Brazil due to our excellence,    innovation and quality in medical diagnostic services. With 50    years of expertise, the company has one of the largest medical    teams in Latin America, composed of nearly 2,000 world-renowned    doctors, and offering more than 3,000 types of laboratory tests    and imaging diagnostics provided by more than 18,000    professionals.  <\/p>\n<p>    Pathways laboratory is accredited by the College of American    Pathologists (CAP) and accredited in accordance with the U.S.    Health and Human Services Clinical Laboratory Improvement    Amendments (CLIA) of 1988. Pathway is also a member of the    American Clinical Laboratory Association (ACLA). The company    consists of more than 40 scientific and medical professionals,    including medical doctors, molecular geneticists, and genetic    counselors, as well as an expert     scientific advisory board.  <\/p>\n<p>    About Pathway Genomics Corporation  <\/p>\n<p>    Pathway Genomics owns and operates an on-site     genetic testing laboratory that is accredited by the    College of American Pathologists (CAP), accredited in    accordance with the U.S. Health and Human Services Clinical    Laboratory Improvement Amendments (CLIA) of 1988, and licensed    by the state of California. Using only a saliva sample, the    company incorporates customized and scientifically validated    technologies to generate personalized reports, which address a    variety of medical issues, including an individuals carrier    status for recessive genetic conditions, food metabolism and    exercise response, prescription drug response, and propensity    to develop certain diseases such as heart disease, type 2    diabetes and cancer. For more information about Pathway    Genomics, visit     <a href=\"http:\/\/www.pathway.com\" rel=\"nofollow\">http:\/\/www.pathway.com<\/a>.  <\/p>\n<p>    About DASA  <\/p>\n<p>    DASA is the largest private medical diagnostics company in    Latin America offering a portfolio of over 3,000 clinical    analysis and imaging tests. In the clinical analysis segment,    samples are collected in more than 500 patient service centers    and analyzed in 11 central laboratories. In the diagnostic    imaging segment, the images are submitted to physicians for    analysis and reporting according to their medical specialty.    For more information about DASA, visit     <a href=\"http:\/\/www.dasa.com.br\" rel=\"nofollow\">http:\/\/www.dasa.com.br<\/a>.  <\/p>\n<\/p>\n<p>More: <\/p>\n<p><a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/pathway-genomics-partners-dasa-largest-114700458.html;_ylt=A2KJjbxoVehP_loAWYX_wgt.\" title=\"Pathway Genomics Partners with DASA, the Largest Private Medical Diagnostics Company in Brazil\">Pathway Genomics Partners with DASA, the Largest Private Medical Diagnostics Company in Brazil<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> SAN DIEGO--(BUSINESS WIRE)-- Pathway Genomics Corporation, a San Diego-based genetic testing laboratory, has partnered with Diagnsticos da Amrica (DASA), the largest private medical diagnostics company in Latin America and the fourth largest provider of diagnostic services in the world. Based in Brazil, DASAs clinical analysis division collects samples from more than 500 patient service centers and has 11 central laboratories.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/genetic-medicine\/pathway-genomics-partners-with-dasa-the-largest-private-medical-diagnostics-company-in-brazil.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[5],"tags":[],"class_list":["post-48229","post","type-post","status-publish","format-standard","hentry","category-genetic-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/48229"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=48229"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/48229\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=48229"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=48229"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=48229"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}